SML3100

AFMT racemate

≥98% (HPLC), E. faecalis pyridoxal-5′-phosphate-dependent tyrosine decarboxylase inhibitor, powder

• Synonym(e): α-(Fluoromethyl)-D/L-tyrosine, (R/S)-α-Fluoromethyltyrosine, (R/S)-2-Amino-3-fluoro-2-(4-hydroxybenzyl)propanoic acid, Alpha-(FluoroMethyl)-D/L-Tyrosine, D/L-AFMT
• Empirische Formel (Hill-System): C₁₀H₁₂FNO₃
• CAS-Nummer: 73804-76-9
• Molekulargewicht: 213.21
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: AFMT racemate, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: OC1=CC=C(C=C1)CC(N)(C(O)=O)CF
• InChI: 1S/C10H12FNO3/c11-6-10(12,9(14)15)5-7-1-3-8(13)4-2-7/h1-4,13H,5-6,12H2,(H,14,15)
• InChI key: ACIQAJKTARSFHQ-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

A racemic mixture of D- and L-AFMT. L-AFMT is reported to selectively inhibt against gut bacteria E. faecalis pyridoxal-5′-phosphate (PLP)-dependent tyrosine decarboxylase (TyrDC)-, but not aromatic amino acid decarboxylase (AADC)-, mediated L-dopa decarboxylation (IC50 = 4.7 μM/cell-free, 1.4 μM/in E. faecalis cultures; 20% human AADC inhibition at 650 μM) via covalent adduct formation with TyrDC co-factor PLP. When co-administered with L-dopa (10 mg/kg) and the AADC inhibitor carbidopa (30 mg/kg) to gnotobiotic mice colonized with E. faecalis, L-AFMT (25 mg/kg) significantly increases L-dopa peak serum concentration.

Covalent inhibtor against L-dopa decarboxylation by gut bacteria E. faecalis tyrosine decarboxylase (TyrDC), but not aromatic amino acid decarboxylase (AADC).

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable